See more : Zhejiang Wanma Co., Ltd. (002276.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Imago BioSciences, Inc. (IMGO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imago BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Unisys Corporation (UIS.SW) Income Statement Analysis – Financial Results
- Eternit S.A. (ETER3.SA) Income Statement Analysis – Financial Results
- Evergold Corp. (EVGUF) Income Statement Analysis – Financial Results
- Somboon Advance Technology Public Company Limited (PSQ.F) Income Statement Analysis – Financial Results
- Shantou Wanshun New Material Group Co., Ltd. (300057.SZ) Income Statement Analysis – Financial Results
Imago BioSciences, Inc. (IMGO)
About Imago BioSciences, Inc.
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.26M | 14.90M | 8.24M |
| General & Administrative | 10.26M | 3.18M | 2.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 10.26M | 3.18M | 2.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 42.52M | 18.07M | 10.66M |
| Cost & Expenses | 42.52M | 18.07M | 10.66M |
| Interest Income | 314.00K | 48.00K | 38.00K |
| Interest Expense | 314.00K | 48.00K | 38.00K |
| Depreciation & Amortization | 6.00K | 1.00K | -208.00K |
| EBITDA | -42.52M | -17.78M | -10.86M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.00M | -18.07M | -10.66M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.00K | 242.00K | -246.00K |
| Income Before Tax | -42.31M | -17.83M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | 3.00K | 0.00 |
| Net Income | -42.31M | -17.83M | -10.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -3.16 | -1.33 | -0.81 |
| EPS Diluted | -3.16 | -1.33 | -0.81 |
| Weighted Avg Shares Out | 13.38M | 13.38M | 13.38M |
| Weighted Avg Shares Out (Dil) | 13.38M | 13.38M | 13.38M |
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Imago BioSciences: The Bone Marrow Cancer Researcher Reaches Milestone
IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Imago BioSciences, Inc. - IMGO
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
SHAREHOLDER ALERT: Weiss Law Investigates Imago BioSciences, Inc.
Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout
Merck Making Moves, to Acquire Imago Biosciences
Why Merck (MRK) Is Buying Imago BioSciences (IMGO) For $1.35 Billion
Source: https://incomestatements.info
Category: Stock Reports